AbbVie Basic Shares Outstanding 2010-2024 | ABBV
AbbVie annual/quarterly basic shares outstanding history and growth rate from 2010 to 2024. Basic shares outstanding can be defined as the number of shares held by shareholders including insiders but not including a company's treasury shares.
- AbbVie basic shares outstanding for the quarter ending September 30, 2024 were $1.769B, a 0.11% increase year-over-year.
- AbbVie basic shares outstanding for the twelve months ending September 30, 2024 were $7.074B, a 0.01% decline year-over-year.
- AbbVie annual basic shares outstanding for 2023 were $1.768B, a 0.17% decline from 2022.
- AbbVie annual basic shares outstanding for 2022 were $1.771B, a 0.06% increase from 2021.
- AbbVie annual basic shares outstanding for 2021 were $1.77B, a 6.18% increase from 2020.
AbbVie Annual Basic Shares Outstanding
(Millions of US $) |
| 2023 |
$1,768 |
| 2022 |
$1,771 |
| 2021 |
$1,770 |
| 2020 |
$1,667 |
| 2019 |
$1,481 |
| 2018 |
$1,541 |
| 2017 |
$1,596 |
| 2016 |
$1,622 |
| 2015 |
$1,625 |
| 2014 |
$1,595 |
| 2013 |
$1,589 |
| 2012 |
$1,577 |
| 2011 |
$1,577 |
| 2010 |
$1,577 |
| 2009 |
$ |
AbbVie Quarterly Basic Shares Outstanding
(Millions of US $) |
| 2024-09-30 |
$1,769 |
| 2024-06-30 |
$1,768 |
| 2024-03-31 |
$1,769 |
| 2023-12-31 |
$1,768 |
| 2023-09-30 |
$1,767 |
| 2023-06-30 |
$1,767 |
| 2023-03-31 |
$1,770 |
| 2022-12-31 |
$1,771 |
| 2022-09-30 |
$1,771 |
| 2022-06-30 |
$1,770 |
| 2022-03-31 |
$1,771 |
| 2021-12-31 |
$1,770 |
| 2021-09-30 |
$1,770 |
| 2021-06-30 |
$1,769 |
| 2021-03-31 |
$1,769 |
| 2020-12-31 |
$1,667 |
| 2020-09-30 |
$1,769 |
| 2020-06-30 |
$1,647 |
| 2020-03-31 |
$1,481 |
| 2019-12-31 |
$1,481 |
| 2019-09-30 |
$1,481 |
| 2019-06-30 |
$1,480 |
| 2019-03-31 |
$1,480 |
| 2018-12-31 |
$1,541 |
| 2018-09-30 |
$1,511 |
| 2018-06-30 |
$1,568 |
| 2018-03-31 |
$1,591 |
| 2017-12-31 |
$1,596 |
| 2017-09-30 |
$1,597 |
| 2017-06-30 |
$1,595 |
| 2017-03-31 |
$1,597 |
| 2016-12-31 |
$1,622 |
| 2016-09-30 |
$1,632 |
| 2016-06-30 |
$1,624 |
| 2016-03-31 |
$1,616 |
| 2015-12-31 |
$1,625 |
| 2015-09-30 |
$1,652 |
| 2015-06-30 |
$1,620 |
| 2015-03-31 |
$1,595 |
| 2014-12-31 |
$1,595 |
| 2014-09-30 |
$1,595 |
| 2014-06-30 |
$1,594 |
| 2014-03-31 |
$1,595 |
| 2013-12-31 |
$1,589 |
| 2013-09-30 |
$1,590 |
| 2013-06-30 |
$1,589 |
| 2013-03-31 |
$1,588 |
| 2012-12-31 |
$1,577 |
| 2012-09-30 |
$1,577 |
| 2012-06-30 |
$1,577 |
| 2012-03-31 |
$1,577 |
| 2011-12-31 |
$1,585 |
| 2011-09-30 |
$1,300 |
| 2011-06-30 |
$1,571 |
| 2011-03-31 |
|
| 2010-12-31 |
|
| 2009-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$312.890B |
$54.318B |
|
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
|
